Shots:
- Leads Biolabs has granted Dianthus exclusive global rights to develop, manufacture, & commercialize LBL-047 as DNTH212 outside of Greater China
- As per the deal, Dianthus will get $20M upfront, $5M in Q4’25, & ~$13M in near-term milestones, with a total potential value of ~$1B incl. development, regulatory, & commercial milestones, plus tiered royalties from mid-single- to low-double-digit rates
- LBL-047, a bispecific fusion protein, depletes plasmacytoid dendritic cells to lower type I interferon production & blocks BAFF/APRIL signaling to inhibit B-cell activity for the treatment of multiple autoimmune diseases; IND application under NMPA’s review
Ref: Leads Biolabs | Image: Leads Biolabs and Dianthus Therapeutics | Press Release
Related News:- Novo Nordisk Enters ~$2.1B Deal with Omeros to Advance Zaltenibart for Rare Blood & Kidney Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
